These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25529320)

  • 21. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study.
    Montgomery ET; Beksinska M; Mgodi N; Schwartz J; Weinrib R; Browne EN; Mphili N; Musara P; Jaggernath M; Ju S; Smit J; Chirenje ZM; Doncel GF; van der Straten A
    J Int AIDS Soc; 2019 May; 22(5):e25283. PubMed ID: 31069957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why consider vaginal drug administration?
    Alexander NJ; Baker E; Kaptein M; Karck U; Miller L; Zampaglione E
    Fertil Steril; 2004 Jul; 82(1):1-12. PubMed ID: 15236978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microbicide preference among young women in California.
    Holt BY; Morwitz VG; Ngo L; Harrison PF; Whaley KJ; Pettifor A; Nguyen AH
    J Womens Health (Larchmt); 2006 Apr; 15(3):281-94. PubMed ID: 16620187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of raloxifene on sexual function in postmenopausal women.
    Kessel B; Nachtigall L; Plouffe L; Siddhanti S; Rosen A; Parsons A
    Climacteric; 2003 Sep; 6(3):248-56. PubMed ID: 14567773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promoting continuous use as a strategy for achieving adherence in a trial of the diaphragm with candidate microbicide.
    Penman-Aguilar A; Swezey T; Turner AN; Bell AJ; Ramiandrisoa FN; Legardy-Williams J; Randrianasolo B; Van Damme K; Dulyx J; Behets F; Jamieson DJ
    AIDS Educ Prev; 2009 Dec; 21(6):512-25. PubMed ID: 20030496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of vaginal gel isoflavones versus no topical treatment in vaginal dystrophy: results of a preliminary prospective study.
    Tedeschi C; Benvenuti C;
    Gynecol Endocrinol; 2012 Aug; 28(8):652-4. PubMed ID: 22316315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaginal films for drug delivery.
    Machado RM; Palmeira-de-Oliveira A; Martinez-De-Oliveira J; Palmeira-de-Oliveira R
    J Pharm Sci; 2013 Jul; 102(7):2069-81. PubMed ID: 23649325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Women's interest in vaginal microbicides.
    Darroch JE; Frost JJ
    Fam Plann Perspect; 1999; 31(1):16-23. PubMed ID: 10029928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Present and future choices of vaginal drug dosage forms. I. Classical forms].
    Guyot M; Fawaz F
    J Pharm Belg; 1993; 48(5):393-406. PubMed ID: 8120794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. By the way, doctor. After stopping Prempro last year, I developed really uncomfortable vaginal dryness. My doctor has recommended the vaginal estrogen ring. Is it safe?
    Robb-Nicholson C
    Harv Womens Health Watch; 2003 Feb; 10(6):8. PubMed ID: 12604440
    [No Abstract]   [Full Text] [Related]  

  • 31. Mucoadhesive and thermogelling systems for vaginal drug delivery.
    Caramella CM; Rossi S; Ferrari F; Bonferoni MC; Sandri G
    Adv Drug Deliv Rev; 2015 Sep; 92():39-52. PubMed ID: 25683694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design.
    Guthrie KM; Dunsiger S; Vargas SE; Fava JL; Shaw JG; Rosen RK; Kiser PF; Kojic EM; Friend DR; Katz DF
    AIDS Res Hum Retroviruses; 2016; 32(10-11):1022-1030. PubMed ID: 26942455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. User experiences and acceptability attributes of the diaphragm and lubricant gel in an HIV prevention trial in southern Africa.
    Sahin-Hodoglugil NN; Montgomery E; Kacanek D; Morar N; Mtetwa S; Nkala B; Philip J; Ramjee G; Cheng H; van der Straten A; The Mira Team
    AIDS Care; 2011 Aug; 23(8):1026-34. PubMed ID: 21480005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The vagina as a route for systemic drug delivery.
    Hussain A; Ahsan F
    J Control Release; 2005 Mar; 103(2):301-13. PubMed ID: 15763615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy.
    Simon JA; Maamari RV
    Climacteric; 2013 Aug; 16 Suppl 1():37-43. PubMed ID: 23848490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Special issue on vaginal drug delivery.
    de Oliveira RP; de Oliveira JM; Caramella C
    Adv Drug Deliv Rev; 2015 Sep; 92():1. PubMed ID: 26452325
    [No Abstract]   [Full Text] [Related]  

  • 37. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey.
    Simon JA; Kokot-Kierepa M; Goldstein J; Nappi RE
    Menopause; 2013 Oct; 20(10):1043-8. PubMed ID: 23571518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Observational study of vaginal pH in healthy Portuguese women.
    Pereira Da Silva D; Martinez De Oliveira J; Negreiro F
    Minerva Ginecol; 2011 Apr; 63(2):203-12. PubMed ID: 21508909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Women's preferences for vaginal antimicrobial contraceptives. I. Methodology.
    Hardy E; de Pádua KS; Jiménez AL; Zaneveld LJ
    Contraception; 1998 Oct; 58(4):233-8. PubMed ID: 9866005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets.
    Garg S; Goldman D; Krumme M; Rohan LC; Smoot S; Friend DR
    Antiviral Res; 2010 Dec; 88 Suppl 1():S19-29. PubMed ID: 21109064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.